CA-SCIENTIST.COM
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that Sanguine Biosciences, a leading biospecimen provider that connects researchers to the biospecimens they need with a direct-to-donor model to accelerate precision medicine and cell and gene therapy research and development, has successfully completed a VERIF.i® on-site assessment. VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.
“Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman. “Scientist.com’s VERIF.i program enables us to further demonstrate the exceptional quality of our biospecimen and biorepository services and the commitment of our team to bridge the gap between donors and researchers.”
Sanguine supports translational, clinical, and cell and gene therapy research, and their services include prospective in-home biospecimen collection directly from their donor network, apheresis products including leukopaks and LeukoLots™, biospecimen inventory, and biorepository services. Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.
“Human biological samples increasingly represent critical tools in the drug discovery and development process, but researchers in the life sciences often have difficulty finding high-quality, ethically sourced human samples,” stated Matt McLoughlin, SVP of Categories & Compliance at Scientist.com. “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”
For more information on VERIF.i, visit https://www.scientist.com/verifi/
About Sanguine Biosciences
Sanguine Biosciences is accelerating the adoption of personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. By merging annotated patient biospecimens with real-world and analytical data, Sanguine delivers actionable biomarker discovery and validation studies that bridge the gap between patients and scientists working on innovative therapies. In supporting translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies, Sanguine has accelerated R&D and increased confidence in drug development and manufacturing pipelines. For the past four years, Sanguine has received the prestigious designation as a "Great Places to Work'' company. In 2023, Sanguine was designated on the Inc. 5000 America's Fastest Growing Private Companies list, Fortune Best Workplaces in BioPharma, and Fortune Best Small Workplaces. Visit sanguinebio.com to learn more.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409671820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
the International Film Criticism Conference Is Launched in Riyadh8.11.2024 18:06:00 CET | Press release
The Saudi Film Commission announced the commencement of the second edition of the International Film Criticism Conference in Riyadh, running from November 6 to 10, 2024. The conference is distinguished by a vast presence of international filmmakers, critics, and cinephiles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108289069/en/ The International Film Criticism Conference is launched in Riyadh (Photo: AETOSWire) The second edition of the Film Criticism Conference is held under the theme "Sound in Cinema", to explore the various impacts of sound on the film experience and its influence on the film industry. The discussions will cover different elements such as film scores, sound effects, and nature sounds. The conference will also include workshops, film screenings, and interactive exhibits. The opening ceremony started with an introductory video about the conference, its objectives, and past achievements, followed by
Panini S.p.A. Launches Expanded BioCred Solution Suite in Europe at Future Identity Festival8.11.2024 16:00:00 CET | Press release
Focus is on the biometric authentication and mobility to enhance customer service and fight identity fraud. Panini S.p.A., a global leader in payments technology and identity solutions, announces the European launch of its BioCred solution suite at Future Identity Festival, in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108392625/en/ Securing the Future, One Identity at a Time. (Photo: Business Wire) BioCred is now available on cloud infrastructure, giving rise to the new BioCred CloudServ, which represents the first step toward a hardware-agnostic solution. As of today, BioCred CloudServ is accessible via the mobile device BioCred SecureTab, the latest addition to the Panini BioCred family of devices, creating a seamlessly integrated flow and delivering a comprehensive, secure identity solution. This turnkey solution, which was presented for the first time at Identity Week America in September, offers a wi
ITEN to Launch the Industrial-Scale Production of Its All-Solid-State Battery Powency Product Family8.11.2024 09:00:00 CET | Press release
Electronica 2024 Trade Fair--ITEN, a pioneer in the development and production of solid-state batteries for electronics markets, today announced the production launch of its new Powency family of rechargeable Li-ion batteries. The new family consists of high-power density batteries, including for now the PWY0150S battery, available in pre-production, and the PWY0250S battery, available as engineering samples. Those first Powency batteries respectively have a capacity of 150µAh and 250µAh. The Powency product family, which is manufactured at the ITEN facility in France, is a testament to the demonstration of ITEN's technological and industrial leadership in the field of solid-state batteries. ITEN will participate in the Electronica trade show in Munich from November 12 to 15, 2024 (Hall B4 - Stand E05) to showcase both PWY0150S and PWY0250S. Powency PWY0150S and PWY0250S, solid-state energy storage in an unmatched form factor The Powency PWS0150S and PWS0250S batteries are designed to
FPT Named Disruptor In HFS Horizons: IoT Service Providers, 20248.11.2024 06:53:00 CET | Press release
Global IT firm FPT, through its subsidiary FPT Software, has been recognized as a Disruptor in HFS Research Horizons report: IoT Service Providers, 2024. This marks the inaugural inclusion of FPT in this prestigious industry assessment, demonstrating its Internet of Things (IoT) capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107263712/en/ (Graphic: Business Wire) The report examines the IoT service capabilities of 23 service providers in the evolving IoT landscape in the age of the Generative Enterprise. It focuses on the supply side, detailing the service providers’ strengths and growth opportunities. FPT’s IoT capabilities encompass a comprehensive range of services designed to address diverse industry needs, from smart homes and healthcare to logistics and manufacturing. With over 3,000 IoT engineers and a portfolio of more than 500 projects, FPT delivers end-to-end IoT solutions, including hardware desig
Analyze Contracts Like a Lawyer - Wordsmith’s First Pass Unlocks Legal Insight for Everyone7.11.2024 23:54:00 CET | Press release
Wordsmith has unveiled First Pass, an AI-powered tool that helps anyone in the business—not just lawyers—analyze agreements and break down key risks. Whether you're in sales, procurement, or finance, First Pass gives you the ability to review contracts instantly, without waiting for legal teams or paying for costly services. “Contracts often hold up business because legal teams are stretched too thin,” said Ross McNairn, CEO of Wordsmith. “First Pass allows anyone from the legal, commercial or other teams to quickly identify risks and key terms, helping move things forward.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108164624/en/ Wordsmith's First Pass lets you review contracts in minutes, not hours. (Graphic: Business Wire) This is a glimpse at the future of legal AI agents. Taking a very specific task end-to-end and making it trivial for anyone to trigger. Try It for Free Users can access First Pass for free by cre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom